摘要
目的评价奥曲肽辅助治疗对急性胰腺炎患者血清CRP、淀粉酶水平的影响。方法 120例急性胰腺炎患者随机分为对照组60例与试验组60例,2组均给予常规治疗以及对症治疗,对照组给予奥美拉唑肠溶胶囊;试验组在对照组的基础上加用醋酸奥曲肽注射液。比较2组临床疗效、治疗前后血清C-反应蛋白(CRP)、淀粉酶(AMS)水平、并发症发生率以及不良反应发生情况。结果治疗后,对照组临床总有效率为75.00%,显著低于试验组的91.67%(P<0.05)。2组治疗后血清CRP、淀粉酶水平均显著降低,且试验组显著小于对照组(P<0.05)。对照组并发症发病率为30.00%,显著高于试验组的13.33%(P<0.05)。对照组不良反应发生率为11.67%,试验组为5.00%,差异无统计学意义。结论奥曲肽辅助治疗对急性胰腺炎患者的临床疗效显著,显著降低血清CRP、淀粉酶水平,安全性高。
Objective To evaluate effect of octreotide on the level of serum CRP and amylase in the treatment of patients with acute pancreatitis.Methods 120 cases with acute pancreatitis were divided into control group and experiment group with each 60 cases. The patients in the both groups were give regular treatment. Patients in the control group were given omeprazole enteric coated capsules and patients in the experiment group revieved octreotide acetate injection. The clinical efficacy,CRP,AMS,incidence of complications and adverse reactions were compared between the two groups.Results The clinical efficacy in experiment group was 91. 67%,which significant higher than that in control group 75. 00%（ P〈0. 05）. The serum level of CRP,AMS decreased after treatment,which in experiment group much lower than the control group（ P〈0. 05）. The complication incidence rate in experiment group was 13. 33%,which significant lower than that in control group 30. 00%（ P〈0. 05）. The adverse drug reactions was not statistically different between the two groups. Conclusion Octreotide in the treatment of acute pancreatitis is effective with high safety and can decrease CRP,AMS levels.
出处
《中国生化药物杂志》
CAS
2016年第1期106-108,共3页
Chinese Journal of Biochemical Pharmaceutics
基金
2011年浙江省医药卫生计划(2011RCB020)
